Belgium
Sustainable change in biomedical research We are pioneering the development of a completely new class of drugs based on the messenger RNA. Executive leader shaping the strategic direction of Oncology R&D to unlock the full potential of CureVac’s mRNA platform in cancer therapeutics.
Smart Immune is a clinical-stage biotechnology company. Through its patented and proprietary ex vivo lymphoid technology, Smart Immune has developed a T-cell progenitor-based cell therapy platform, called the ProTcell™ platform. It has been designed to enable rapid and full re-arming of the immune system, so patients can fight life-threatening disorders. Leading the clinical development strategy and operations for allogeneic transplantation and cell & gene therapy programs.
Celyad is a biopharmaceutical company focused on translating breakthrough cell-based research into innovative therapeutics to improve the outcome of severe diseases. The Company is currently developing clinical stage cell therapies. In oncology, the company is developing CAR T-cell therapies. The lead product NKG2D CAR T-cell is an autologous T-cell transduced with a NKG2D receptor present on Natural Killer (NK) cells that binds to numerous types of cancer cells, including blood cancers and solid tumors. Lead and define the global clinical strategy , in alignment with Celyad’s Corporate Clinical Development strategy and overall business strategy.
Lead the R&D and Early Clinical Development Business Unit (INCUBATOR) for Cancer Immunotherapeutics with the objective to bring product, companion diagnostics and predictive biomarkers from discovery to registration development in a fully integrated and transversal model. Leadership of a global team focused on integrating translational science into drug and biomarkers discovery and development to improve the speed and probability of success of bringing novel cancer immunotherapies to patients. Team of 66 persons with diverse background such as MDs, scientists (immunology, biology, molecular biology) and clinical operations. Entrepreneurial mindset in evaluating, establishing and leading strategic partnerships and collaborations with external institutions, pharmaceutical and biotechnology industry partners. Achieve goals through scientific and business excellence focused on implementation and execution. Experiences include leading line and matrix management, as well as external business development.
Director (2003-2012), Vice President (2013). Leading and accountable for the co-ordination and management of the WW GSK cancer vaccines early clinical development program (MAGE-A3, WT1, NY-ESO-1, PRAME, HER-2, Tn, …) with the objective to bring product, companion diagnostics and predictive biomarkers from discovery to proof of concept. Actively participating in the global strategy of cancer vaccines clinical development and the cancer antigens portfolio. Identify, establish and lead strategic partnerships and collaborations with external institutions and pharmaceutical industry partners. Based in USA, Philadelphia (2008-2010).